Citing failures in patient monitoring, the FDA has suspended 11 clinical trials a New Jersey cancer center has been running for a nearby biotechnology firm, Immunomedics (Morris Plains, NJ). The company and the nonprofit Garden State Cancer Center at the Center for Molecular Medicine and Immunology were founded and are run by the same man, David Goldenberg. “We believe that virtually all of the issues raised by the FDA involve paperwork and record-keeping deficiencies, not treatment,” said Goldenberg on September 26. “We are confident that our patients have been treated with the highest level of professionalism, safety, and concern for their welfare.” In a related action, the US attorney's office in New Jersey subpoenaed a former clinical trial investigator at Garden State demanding all documents and communications related to Immunomedics and the center; the investigator resigned in August. Shares of Immunomedics, which is working on binding radioisotopes to monoclonal antibodies as cancer treatments, fell 17% to $18 in early October.